Advertisement

Clinical and Translational Oncology

, Volume 10, Issue 8, pp 486–492 | Cite as

Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level

  • Jaime Sanz OrtizEmail author
Reviews

Abstract

Anemia is the most frequent hematologic abnormality among cancer patients. Its pathophysiology comprises reduction in erythrocyte half-life, poor iron reutilization by the bone marrow, and inadequate response to erythropoietin (EPO), with reduced endogenous EPO (eEPO) levels. Current treatment implies the use of erythropoiesis-stimulating agents (ESA), to which 35–48% of patients show primary resistance. The search for predictors of response to ESA treatment has been inconclusive. Iron or vitamin deficiency, the recent need for transfusion, or a lack of hemoglobin increase within the first 2–4 weeks usually predict resistance to ESA. High serum eEPO levels at treatment initiation (> 100–150 mU/ml) may also predict resistance, especially in hematologic malignancies, but the results in solid tumors are not consistent. Although patients with cancer-related anemia show higher eEPO levels than patients without anemia, there is extreme variability among individuals. Future studies are needed to clarify eEPO usefulness in predicting response to ESA treatment.

Keywords

Anemia Erythropoiesis-stimulating agents Erythropoietin Drug resistance Risk factors Neoplasms 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Groopman JE, Itri LM (1999) Chemotherapy-induced anaemia in adults: incident and treatment. J Natl Cancer Inst 91:1616–1634PubMedCrossRefGoogle Scholar
  2. 2.
    Charuruks N, Voravud N, Limpanasithikul W (2001) Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favorable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients. J Clin Lab Anal 15:260–266PubMedCrossRefGoogle Scholar
  3. 3.
    Benson EW, Hardy R, Chaffin H et al (2000) New automated chemiluminescent assay for erythropoietin. J Clin Lab Anal 14:271–273PubMedCrossRefGoogle Scholar
  4. 4.
    Canaparo R, Casale F, Muntoni E et al (2000) Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Brit J Pharmacol 50:146–153CrossRefGoogle Scholar
  5. 5.
    Tas F, Eralp Y, Basaran M et al (2002) Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 25:371–379PubMedCrossRefGoogle Scholar
  6. 6.
    Del Mastro L, Gennari A, Donati S (1999) Chemotherapy of non-small-cell lung cancer: role of erythropoietin in the management of anemia. Ann Oncol 10:S91–S94PubMedCrossRefGoogle Scholar
  7. 7.
    Demetri GD (2001) Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 84:31–37PubMedCrossRefGoogle Scholar
  8. 8.
    Rajeswaran A, Trojan A, Burnand B, Giannelli M (2008) Efficacy and side effects of cisplatin-and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59:1–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Ludwig H, Van Belle S. Barret-Lee P et al (2004) The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J of Cancer 40:2293–2306CrossRefGoogle Scholar
  10. 10.
    Fisher JW (2003) Erythropoietin: physiology and pharmacology update. EBM 228:1–14Google Scholar
  11. 11.
    Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG (2007) Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin. Biochim Biophys Acta 1776:1–9PubMedGoogle Scholar
  12. 12.
    P. Ghezzi and M. Brines (2004) Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 11:S37–S44PubMedCrossRefGoogle Scholar
  13. 13.
    Koury MJ, Sawyer ST, Brant SJ (2002) New insights into erythropoiesis Curr Opin Hematol 9:93–100PubMedCrossRefGoogle Scholar
  14. 14.
    Langer CJ, Hirsch FR, Cortés-Funes H et al (2003) Targeted molecular mechanisms of epoetin alpha. Lung Cancer 41:S133–S145PubMedCrossRefGoogle Scholar
  15. 15.
    Boogaerts M (2006) Pleiotropic effects of erythropoietin in neuronal and vascular systems. Curr Med Res Opin 22(Suppl. 4):15–22CrossRefGoogle Scholar
  16. 16.
    Brines M, Cerami A (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6:484–494PubMedCrossRefGoogle Scholar
  17. 17.
    Maraveyas A, Pettengell R (1998) What is the role of erythropoietin in patients with solid tumors? Ann Oncol 9:255–260CrossRefGoogle Scholar
  18. 18.
    Seidenfeld J, Piper M, Bohlius J et al (2006) Comparative effectiveness of epoetin and darbepoetin for managing anaemia in patients undergoing cancer treatment. Comparative Effectiveness Review No. 3 (Prepared by the BlueCross and BlueShield Association Technology Evaluation Center Evidence-Based Practice Center under Contract No. 290-02-0026). Agency for Healthcare Research and Quality. http://www.effectivehealthcare.ahrq.gov. (Cited 23 May 2006)
  19. 19.
    Jones M, Schenkel B, Just J et al (2004) Epoetin al pha improves quality of life in patients with can cer: results of metaanalysis. Cancer 101: 1720–1732. Erratum in: (2005) Cancer 103:1984PubMedCrossRefGoogle Scholar
  20. 20.
    Hedenus M, Vansteenkiste J, Kotasek D et al (2005) Darbepoetin alpha for the treatment of chemotherapy-induced anaemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 23:6941–6948PubMedCrossRefGoogle Scholar
  21. 21.
    Bohlius J, Wilson J, Seidenfeld J et al (2006) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 3:CD003407Google Scholar
  22. 22.
    Rizzo JD, Somerfield MR, Hagerty KL et al (2008) Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. J Clin Oncol 26:132–149PubMedCrossRefGoogle Scholar
  23. 23.
    Bokemeyer C, Aapro MS, Courdi A et al (2007) Erythropoiesis-stimulating agents-ESAs: The 2007 position of the EORTC working party. Presented at Live Expert, e-European School of Oncology, 21. September 2007. http://services.choruscall.eu/links/eso070921.html. Cited 24 December 2007
  24. 24.
    National Comprehensive Cancer Network (NCCN) (2007) Practice guidelines in oncology: cancer-and treatment-related anaemia. Ver. 3. Jenkintown, PA: NCCN. www.nccn.org/professionals/physician_gls/PDF/anaemia.pdf. Cited 24 December 2007Google Scholar
  25. 25.
    (2004) Epoetin: for better or for worse?[editorial]. Lancet Oncol 5:1Google Scholar
  26. 26.
    Bohlius J, Langensiepen S, Schwarzer G et al (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97:489–498PubMedGoogle Scholar
  27. 27.
    Lipsic E, van der Meer P, Voors AA et al (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin alpha in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20: 135–141PubMedCrossRefGoogle Scholar
  28. 28.
    Yasuda Y, Fujita Y, Matsuo T et al (2003) Erythropoietin regulates tumor growth on the human malignancies. Carcinogenesis 24:1021–1029PubMedCrossRefGoogle Scholar
  29. 29.
    Leyland-Jones B, Semiglazov V, Pawlicki M et al (2005) Maintaining normal haemoglobin levels with epoetin alpha in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960–5972PubMedCrossRefGoogle Scholar
  30. 30.
    Silva M, Benito A, Sanz C (1999) Erythropoietin can induce the expression of bcl-x through Stat5 in erythropoietin dependent progenitor cell lines. J Biol Chem 274:22165–22169PubMedCrossRefGoogle Scholar
  31. 31.
    Henke M, Laszig R, Rübe C et al (2003) Erythropoietin to treat head an neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 362:1255–1260PubMedCrossRefGoogle Scholar
  32. 32.
    LaMontagne KR, Butler J, Marshall DJ et al (2006) Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5: 347–355PubMedCrossRefGoogle Scholar
  33. 33.
    Hardee ME, Rabbani ZN, Arcasoy MO et al (2006) Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 5:356–361PubMedCrossRefGoogle Scholar
  34. 34.
    Kirkpatrick JP, Hardee ME, Snyder SA et al (2006) The effect of darbepoetin alpha on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. Radiat Res 165:192–201PubMedCrossRefGoogle Scholar
  35. 35.
    Kjellen E, Sasaki Y, Kjellstrom J et al (2006) Recombinant erythropoietin beta enhances growth of xenografted human squamous cell carcinoma of the head and neck after surgical trauma. Acta Otolaryngol 126:545–547PubMedCrossRefGoogle Scholar
  36. 36.
    Pinel S, Barberi-Heyob M, Cohen-Jonathan E et al (2004) Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. Int J Radiat Oncol Biol Phys 59:250–259PubMedGoogle Scholar
  37. 37.
    Drüeke T (2001) Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16(Suppl 7):25–28PubMedGoogle Scholar
  38. 38.
    Beguin Y (1998) Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer. Med Oncol 15:S38–S46PubMedGoogle Scholar
  39. 39.
    Thomas C, Thomas L (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48:1066–1076PubMedGoogle Scholar
  40. 40.
    Katodritou E, Terpos E, Zervas K et al (2007) Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol 86:369–376PubMedCrossRefGoogle Scholar
  41. 41.
    Rizzo JD, Seidenfeld J, Piper M et al (2001) Erythropoietin: a paradigm for the development of practice guidelines. Hematology (Am Soc Hematol Educ Program) 1:10–30Google Scholar
  42. 42.
    Braun J, Lindner K, Schreiber M et al (1997) Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 12:1173–1181PubMedCrossRefGoogle Scholar
  43. 43.
    Goram AL (2000) Factors and predictors of response with epoetin alpha for chemotherapy-related anemia. J Pharm Technol 16:227–235Google Scholar
  44. 44.
    Cazzola M, Ponchio L, Pedrotti C et al (1996) Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 81:434–441PubMedGoogle Scholar
  45. 45.
    Littlewood TJ, Zagari M, Pallister P (2005) Pretreatment erythropoietin levels cannot be used to predict individual response to epoetin alpha in anaemic cancer patients. Curr Med Res Opin 21(Suppl 2):S19–S21Google Scholar
  46. 46.
    Kolesar JM, Duren BA, Baranski BG (2004) Retrospective evaluation of response to epoetin alpha in patients with hematologic disorders. J Oncol Pharm Pract 10:1–6CrossRefGoogle Scholar
  47. 47.
    Littlewood TJ, Zagari M, Pallister C et al (2003) Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 8:99–107PubMedCrossRefGoogle Scholar
  48. 48.
    Glaspy J, Cavill I (1999) Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology 13:461–473PubMedGoogle Scholar
  49. 49.
    Henry D, Abels R, Larholt K (1995) Prediction of response to recombinant human erythropoietin (r-HuEPO/Epoetin-alpha) therapy in cancer patients. Blood 85:1676–1678PubMedGoogle Scholar
  50. 50.
    Ludwig H, Fritz E, Leitgeb C et al (1994) Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84:1056–1063PubMedGoogle Scholar
  51. 51.
    Demetri G, Kris M, Wade J et al (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: results from a Prospective Community Oncology Study. J Clin Oncol. 16: 3412–3425PubMedGoogle Scholar
  52. 52.
    Boccia R, Malik IA, Raja V et al (2006) Darbepoetin alpha administered every three weeks is effective for the treatment of chemotherapy-induced anaemia. Oncologist 11: 409–417PubMedCrossRefGoogle Scholar
  53. 53.
    Trelle S, Piper M, Bohlius J et al (2006) Predictive factors of response to recombinant human erythropoietin: quality and results of studies identified by a systematic review. Onkologie 29(Suppl 3):66Google Scholar
  54. 54.
    Österborg, M.A. Boogaerts, R. Cimino et al (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma: a randomized multicenter study. Blood 87:2675–2682PubMedGoogle Scholar
  55. 55.
    Boogaerts M, Coiffier B, Kainz C (2003) Impact of epoetin β on quality of life in patients with malignant disease. Brit J. Cancer 88:988–995PubMedCrossRefGoogle Scholar
  56. 56.
    Hedenus M, Adriansson M, San Miguel J et al (2003) Efficacy and safety of darbepoetin alpha in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Brit J Haematol 122:394–403CrossRefGoogle Scholar
  57. 57.
    Steinmetz T, Hellmich M, Neise M et al (2007) Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors. Oncologist 12:748–755PubMedCrossRefGoogle Scholar
  58. 58.
    Belon J, Cervera JM, Martinez A et al (2006) Darbepoetin alpha at weekly fixed doses. Clinical experience in Spanish centers. Drugs Today (Barc) 42(Suppl 10):1–12Google Scholar
  59. 59.
    Agoram B, Heatherington AC, Gastonguay MR (2006) Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alpha in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J 8(3):E552–563PubMedCrossRefGoogle Scholar
  60. 60.
    Ross SD, Allen IE, Probst CA et al (2007) Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 12:1264–1273PubMedCrossRefGoogle Scholar
  61. 61.
    Kato A, Tsuji T, Luo J et al (2008) Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 28:115–121PubMedCrossRefGoogle Scholar
  62. 62.
    Hedenus M, Hansen S, Taylor K et al (2002) Randomized, dose-finding study of darbepoetin alpha in anemic patients with lymphoproliferative malignancies. Brit J Cancer 119:79–86Google Scholar
  63. 63.
    Glimelius B, Linné T, Hoffman et al (1998) Epoetin beta in the treatment of anaemia in patients with advanced gastrointestinal cancer. J Clin Oncol 16:434–440PubMedGoogle Scholar
  64. 64.
    Cazzola M, Diethelm M, Battistel B et al (1995) Recombinant human erythropoietin in the anaemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 86: 4446–4453PubMedGoogle Scholar
  65. 65.
    Cazzola M, Beguin Y, Kloczko J et al (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Brit J Cancer 122:386–393Google Scholar
  66. 66.
    Hellstrom-Lindberg E, Negrin R, Stein R et al (1997) Erythroid response to treatment with GCSF plus erythropoietin for the anemia of patients with myelodysplastic syndromes: proposal for a predictive model. Brit J Haematol 99:344–351CrossRefGoogle Scholar
  67. 67.
    Fjornes T, Wiedemann GJ, Sack K et al (1998) Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anemic tumor patients on chemotherapy. Oncol Rep 5:81–86PubMedGoogle Scholar
  68. 68.
    Canon J, Vansteenkiste J, Bodoky G et al (2006) Randomized double-blind, active-controlled trial of every-3-week Darbepoetin alpha for the treatment of chemotherapy induced anaemia. J Nat Can Inst 98:273–283CrossRefGoogle Scholar
  69. 69.
    Glaspy J, Demetri G, Cremieux P (1999) Does baseline endogenous erythropoietin level impact haemoglobin (Hb) response to r-HuEPO. Blood 94(10 Suppl. 1 Part 2):15bGoogle Scholar
  70. 70.
    Kostova G, Siljanovski N (2005) Erythropoietin production in patients with malignant lymphoma. Prilozi 26:157–168PubMedGoogle Scholar
  71. 71.
    Ozguroglu M, Arun B, Demir G et al (2000) Serum erythropoietin level in anemic cancer patients. Mescal Oncology 17:29–34CrossRefGoogle Scholar
  72. 72.
    Fujisaka Y, Tamura T, Ohe Y et al (2006) Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients. Jpn J Clin Oncol 36:477–482PubMedCrossRefGoogle Scholar
  73. 73.
    Charuruks N, Limpanasithikul W, Voravud N et al (2000) Erythropoietin level and haematologic parameters in healthy adults. J Med Assoc Thai 83: 1267–1273PubMedGoogle Scholar
  74. 74.
    Yamazaki C, Watanabe Y, Sakamoto N (1993) Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients. Japanese J Nephrol 35: 1233–1242Google Scholar
  75. 75.
    Vansteenkiste J, Pirker R, Massuti B et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alpha in lung cancer patients receiving chemotherapy. J Natl Cancer I 94:1211–1220Google Scholar
  76. 76.
    Heatherington AC, Glaspy J, Kotasek D et al (2001) Changes endogenous erythropoietin and the pharmacokinetics of darbepoetin alpha in patients with non-myeloid malignancies receiving chemotherapy. Blood 98:298a–299aGoogle Scholar
  77. 77.
    Kaczorowska-Hac B, Balcerska A (2003) Endogenous erythropoietin levels in children with malignancies disorders. Acta Haematol Pol 34:231–237CrossRefGoogle Scholar
  78. 78.
    Aapro M, Abraham I, Bokemeyer C et al (2008) The background and methodology of the Anaemia Cancer Treatment (ACT) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines. Support Care Cancer 16:193–200PubMedCrossRefGoogle Scholar

Copyright information

© Feseo 2008

Authors and Affiliations

  1. 1.Medical Oncology ServiceHospital Marqués de ValdecillaSantanderSpain

Personalised recommendations